Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
17 09 2020
Historique:
received: 13 05 2020
revised: 12 06 2020
accepted: 31 07 2020
pubmed: 19 8 2020
medline: 25 9 2020
entrez: 19 8 2020
Statut: ppublish

Résumé

Blood myeloid cells are known to be dysregulated in coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2. It is unknown whether the innate myeloid response differs with disease severity and whether markers of innate immunity discriminate high-risk patients. Thus, we performed high-dimensional flow cytometry and single-cell RNA sequencing of COVID-19 patient peripheral blood cells and detected disappearance of non-classical CD14

Identifiants

pubmed: 32810439
pii: S0092-8674(20)30993-4
doi: 10.1016/j.cell.2020.08.002
pmc: PMC7405878
pii:
doi:

Substances chimiques

Leukocyte L1 Antigen Complex 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1401-1418.e18

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests A. Silvin, N.C., M.F., E. Solary, and F. Ginhoux are inventors of patent EP 20305624.7, “Methods for detecting and treating COVID patients requiring intensive care,” submitted on June 9, 2020 under Gustave Roussy.

Références

Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
J Virol. 2004 May;78(9):4444-53
pubmed: 15078925
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Crit Care Med. 2009 Oct;37(10):2746-52
pubmed: 19707128
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Cell. 2014 Aug 28;158(5):1187-1198
pubmed: 25171416
Biometrics. 2020 Mar;76(1):337-347
pubmed: 31399994
J Clin Invest. 2019 Jul 29;129(9):3625-3639
pubmed: 31355779
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
J Clin Invest. 2018 May 1;128(5):1852-1866
pubmed: 29611822
N Engl J Med. 2020 May 7;382(19):1861-1862
pubmed: 32220206
Oncotarget. 2017 Feb 7;8(6):9053-9066
pubmed: 28118607
Blood. 2015 Dec 10;126(24):2601-10
pubmed: 26443621
Nat Immunol. 2011 Jul 03;12(8):778-85
pubmed: 21725321
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
FEBS Lett. 2014 Jun 13;588(13):2141-6
pubmed: 24796790
J Clin Invest. 2017 Jun 1;127(6):2133-2147
pubmed: 28504650
Nat Immunol. 2017 Jun;18(6):622-632
pubmed: 28459433
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Curr Opin Virol. 2012 Jun;2(3):264-75
pubmed: 22572391
Nat Commun. 2018 Dec 21;9(1):5455
pubmed: 30575719
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
Cell Mol Immunol. 2020 Sep;17(9):992-994
pubmed: 32620787
Blood. 2019 Jul 11;134(2):134-146
pubmed: 31076441
Nat Rev Immunol. 2020 Jun;20(6):338
pubmed: 32327718
Nature. 2017 Apr 6;544(7648):105-109
pubmed: 28329764
PLoS One. 2013 Jul 18;8(7):e68694
pubmed: 23874727
Virus Res. 2007 Dec;130(1-2):228-40
pubmed: 17669539
Immunology. 2012 Oct;137(2):172-82
pubmed: 22804476
Virus Res. 2005 Jan;107(1):93-101
pubmed: 15567038
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Blood Adv. 2019 Nov 26;3(22):3562-3574
pubmed: 31738831
Inflammation. 2017 Feb;40(1):58-67
pubmed: 27704310
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
J Immunol. 2015 Jan 15;194(2):575-83
pubmed: 25505274
Lancet. 2020 Mar 21;395(10228):e52
pubmed: 32171074
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Nat Rev Immunol. 2019 Apr;19(4):255-265
pubmed: 30816340
Ann Oncol. 2020 Jul;31(7):961-964
pubmed: 32247642
Blood. 2020 Aug 13;136(7):909-913
pubmed: 32294158
J Clin Invest. 2013 Nov;123(11):4595-611
pubmed: 24216507
Immunity. 2018 Feb 20;48(2):364-379.e8
pubmed: 29466759
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Cell. 2020 Jun 25;181(7):1475-1488.e12
pubmed: 32479746
Ann Oncol. 2017 Nov 1;28(11):2741-2746
pubmed: 29059273
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Caspian J Intern Med. 2013 Spring;4(2):627-35
pubmed: 24009950
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Expert Opin Investig Drugs. 2018 Apr;27(4):339-348
pubmed: 29534618
Leukemia. 2017 Oct;31(10):2172-2180
pubmed: 28096534
J Immunol. 1996 Feb 1;156(3):1284-95
pubmed: 8558009
Immunity. 2018 Oct 16;49(4):595-613
pubmed: 30332628
Front Immunol. 2018 Jun 11;9:1298
pubmed: 29942307
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
J Exp Med. 2019 Sep 2;216(9):2150-2169
pubmed: 31239386
Cell Rep. 2014 Dec 24;9(6):2112-23
pubmed: 25497086
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):35-42
pubmed: 27765768
J Immunol. 2008 Mar 1;180(5):3366-74
pubmed: 18292562
Pediatrics. 2015 Jan;135(1):e92-8
pubmed: 25452656
Sci Rep. 2015 Dec 03;5:17554
pubmed: 26631542
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Blood. 2016 Dec 22;128(25):2960-2975
pubmed: 27737891
Haematologica. 2019 Aug 14;:
pubmed: 31413091

Auteurs

Aymeric Silvin (A)

INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Nicolas Chapuis (N)

Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France.

Garett Dunsmore (G)

INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Anne-Gaëlle Goubet (AG)

INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Agathe Dubuisson (A)

INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Lisa Derosa (L)

INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Carole Almire (C)

Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France.

Clémence Hénon (C)

INSERM U981, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Olivier Kosmider (O)

Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France.

Nathalie Droin (N)

INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France; INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Philippe Rameau (P)

INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Cyril Catelain (C)

INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Alexia Alfaro (A)

INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Charles Dussiau (C)

Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France.

Chloé Friedrich (C)

Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France.

Elise Sourdeau (E)

Service des Urgences, AP-HP, Hôpital Hôtel-Dieu, Paris 75014, France.

Nathalie Marin (N)

Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, Paris 75014, France.

Tali-Anne Szwebel (TA)

Service de Médecine Interne, AP-HP, Hôpital Cochin, Paris 75014, France.

Delphine Cantin (D)

Service des Urgences, AP-HP, Hôpital Hôtel-Dieu, Paris 75014, France.

Luc Mouthon (L)

Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service de Médecine Interne, AP-HP, Hôpital Cochin, Paris 75014, France.

Didier Borderie (D)

Service de Diagnostic Biologique Automatisé, AP-HP, Hôpital Cochin, Paris 75014, France.

Marc Deloger (M)

INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Delphine Bredel (D)

INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Severine Mouraud (S)

INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Damien Drubay (D)

INSERM U1018, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Muriel Andrieu (M)

Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France.

Anne-Sophie Lhonneur (AS)

Laboratoire de Virologie, AP-HP, Hôpital Cochin, Paris 75014, France.

Véronique Saada (V)

Département de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Annabelle Stoclin (A)

Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Christophe Willekens (C)

INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département d'Hématologie, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Fanny Pommeret (F)

Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Frank Griscelli (F)

Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Lai Guan Ng (LG)

Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos Building #3-4, Biopolis, Singapore 138648, Singapore.

Zheng Zhang (Z)

Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China.

Pierre Bost (P)

Systems Biology Group, Department of Computational Biology and USR 3756, Institut Pasteur and CNRS, Paris 75015, France; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Ido Amit (I)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Fabrice Barlesi (F)

Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Aurélien Marabelle (A)

INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy Cancer Campus, Villejuif 94800, France.

Frédéric Pène (F)

Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, Paris 75014, France.

Bertrand Gachot (B)

Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Fabrice André (F)

Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France; INSERM U981, Gustave Roussy Cancer Campus, Villejuif 94800, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France.

Laurence Zitvogel (L)

INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France; Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, Villejuif 94800, France.

Florent Ginhoux (F)

Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos Building #3-4, Biopolis, Singapore 138648, Singapore; Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore. Electronic address: florent_ginhoux@immunol.a-star.edu.sg.

Michaela Fontenay (M)

Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France. Electronic address: michaela.fontenay@aphp.fr.

Eric Solary (E)

INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France; Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France. Electronic address: eric.solary@gustaveroussy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH